CatalYm, a biotechnology company developing visugromab, a first-in-class anti-GDF-15 antibody for solid tumors and cachexia, has announced Peter Garcia as its chief financial officer.
Garcia brings over three decades of biotechnology and oncology financial leadership experience. Most recently, he served as CFO of Bluejay Therapeutics, which was acquired by Mirum Pharmaceuticals. Previously, he held CFO roles at ALX Oncology Holdings, where he led the company’s IPO, and at PDL BioPharma.
Throughout his career, Garcia has raised more than $2.5 billion in debt and equity capital, including two IPOs, numerous follow-on offerings, and structured financings. He also has earlier experience in senior finance and controller roles at Amgen. Garcia holds an MBA in finance and accounting from UCLA Anderson School of Management and a BA in economics and sociology with honors from Stanford University.
eGenesis, a biotechnology company developing human-compatible engineered organs for transplantation, has appointed Glenn S. Vraniak as chief financial officer as the company advances clinical studies across multiple programs including EGEN-2784 for kidney failure and a program for acute-on-chronic liver failure.
Vraniak brings over two decades of executive leadership experience across biotechnology, medical technology, and specialty pharmaceuticals with a strong track record of leading capital raising initiatives, IPOs, and strategic transactions. Most recently, he served as chief financial officer of Inversago Pharma, where he led the company’s growth strategy and financing activities, including a $70 million Series C financing. He also played a key role in Inversago’s eventual acquisition by Novo Nordisk in a transaction valued at approximately $1.1 billion. Previously, Vraniak served as CFO of Evaxion Biotech, Valeo Detection Systems, and electroCore.
He also served on the board of directors of Apollomics Inc., where he chaired the Audit Committee.
Hansa Biopharma, a commercial-stage biopharmaceutical company developing and commercializing novel immunomodulatory therapies, named Adam Cutler as chief financial officer and a member of the executive committee, effective June 22, 2026, succeeding Evan Ballantyne, who will retire after supporting the transition through July 10, 2026.
Cutler has over 25 years of biotechnology finance experience, including previous CFO roles at Mural Oncology, Q32 Bio, and Molecular Templates. He has experience in capital raising, investor relations, and strategic planning across corporate finance, investment banking, and equity research.
Immuneering Corporation, a late-stage clinical oncology company, has appointed Andrew Gengos as chief financial officer, effective July 16, 2026. With over 25 years of leadership experience in biotechnology, Gengos most recently served as chief financial officer and head of corporate development at Terns Pharmaceuticals.
At Immuneering, Gengos will oversee financial strategy, capital allocation, investor relations, business development, and corporate development activities as the company advances atebimetinib, its lead oncology candidate in Phase III, and a pipeline of other deep cyclic inhibitors.
Previously, he served as chief financial officer and chief business officer of Athira Pharma, Inc. (now LeonaBio, Inc.), and as chief business officer of Cyteir Therapeutics, Inc., where he led the finance organization that successfully completed the company’s initial public offering. Earlier in his career, he served as chief executive officer of ImmunoCellular Therapeutics, Ltd. and Neuraltus Pharmaceuticals, Inc. He also spent eight years as vice president of strategy and corporate development at Amgen Inc., where he helped shape the company’s long-term strategic priorities and business development initiatives. Gengos began his career at Morgan Stanley and later joined McKinsey & Company, advancing from associate to senior engagement manager. He holds an MBA from the UCLA Anderson School of Management and a BS in chemical engineering from the Massachusetts Institute of Technology.
Kazia Therapeutics, a clinical-stage oncology company advancing therapies designed to reprogram cancer biology and overcome treatment resistance, has appointed James Levine as chief financial officer, effective June 1, 2026.
Levine has over 20 years of experience in investment banking and biotech financial leadership. He previously held CFO roles at Cardiff Oncology and Cidara Therapeutics, where he led major pharmaceutical partnerships worth over $1.3 billion combined. He also spent 12 years as a managing director at Goldman Sachs, advising pharma and biotech clients on strategic transactions. Levine holds an MBA from The Wharton School at the University of Pennsylvania.
Biotechnology company Neuraptive Therapeutics, which is developing novel therapeutics and medical products to address peripheral nerve injuries, has appointed William “Bill” MacKenzie as senior vice president – finance, where he will lead the enterprise finance function and develop the company’s operational infrastructure.
MacKenzie brings over a decade of biotech financial leadership, having served as a consultant and head of finance at Neuraptive since March 2025. Previously, he held executive roles including head of accounting and head of FP&A for revenue, commercial, and R&D at companies including Sage Therapeutics (2022-2024), Prelude Therapeutics (2021-2022), LifeScan (2020-2021), and Zyla Life Sciences (2015-2020). His experience spans public, private, and PE-backed environments with experience navigating multiple FDA-approved products and complex corporate restructurings.
Pfizer Inc. has announced that Cecile Guegan will serve as interim chief financial officer, effective August 16, 2026, following the departure of Dave Denton, chief financial officer, who is stepping down on August 15, 2026, to pursue a professional opportunity outside of the pharmaceutical industry in consumer goods.
Guegan, currently senior vice president, finance, Global Biopharmaceutical Business, brings over two decades of experience at Pfizer with deep global financial experience leading finance across a wide range of complex and strategic portfolios, research and development, and several regions.
In her current role, she is directly responsible for the financial operations and reporting of Pfizer’s biopharmaceutical business across all therapeutic areas and geographies. She has a proven track record of leading important enterprise initiatives, including the integration of Seagen into Pfizer in 2024. Guegan holds a master’s degree in business from Brest Business School.
Quanterix Corporation, a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, has named Jason Faessler as chief financial officer, effective June 22, 2026.
Faessler brings extensive finance leadership experience in the life science tools industry. Most recently, he served as senior vice president at Bruker Corporation, leading global FP&A and the Americas Finance organization with responsibilities including strategic planning, operational finance, and capital decision-making. Previously, he held senior finance leadership positions at PAREXEL, leading its Early- and Late-Phase Clinical divisions. He also held senior financial management roles at EMC (now Dell) and Harvard Business Publishing.
Clinical-stage biopharmaceutical company Retension Pharmaceuticals has appointed Alex Schwartz as chief financial officer as the company advances RTN-001 through its ongoing Phase IIb trial for hypertension treatment.
Schwartz brings over 15 years of finance experience spanning both corporate leadership and Wall Street equity research. Most recently, he served as vice president of financial planning & analysis and investor relations at Ventyx Biosciences, which was acquired by Eli Lilly in March 2026. He also held senior finance positions at Allakos, NGM Biopharmaceuticals, and Esperion Therapeutics. Earlier in his career, Schwartz worked as a biotechnology equity research analyst at Stifel, covering cardiovascular therapeutics.
He holds a BS in finance from Indiana University’s Kelley School of Business and an MBA from Boston College’s Carroll School of Management.
Savara Inc., a clinical-stage biopharmaceutical company focused on rare respiratory diseases, has announced that Robert Lutz will assume the additional role of chief financial officer following the departure of Dave Lowrance, chief financial and administrative officer, who is stepping down effective July 15, 2026, for health-related reasons after nearly 10 years with the company.
Lutz, expanding from his current position as chief operating officer which he has held since February 2023, brings over two decades of operational leadership experience in the pharmaceutical industry including finance strategy, equity and debt raises, financial planning and analysis, investor relations, business development deal execution, and commercial/operational business analytics. Previously, he served as chief financial and business officer of iBio, Inc. and Strongbridge Biopharma plc, with earlier leadership roles at Shire Plc. and Cinergy Corp. He began his career as a financial analyst at Goldman Sachs. Lutz holds a BA in economics and computer science from Amherst College and an MBA from the Kellogg School of Management.
Syntis Bio, a clinical-stage biopharmaceutical company advancing novel oral therapeutics that leverage the small intestine, has appointed Matthew Dallas as chief financial officer. Dallas brings over 25 years of financial expertise and management experience in the life sciences industry.
Most recently, he served as chief financial officer of Pulmocide, overseeing capital strategy, finance, and investor relations. Previously, he held CFO roles at Zealand Pharma (a Danish biotechnology company focusing on metabolic diseases including diabetes and obesity), AVEO Oncology, and CoLucid Pharmaceuticals, where he helped lead the company’s initial public offering and subsequent acquisition by Eli Lilly and Company. Dallas holds a BS in finance from the University of Tennessee, Knoxville.
These announcements are from May 26 through June 23, 2026, as posted on BusinessWire, PRNewswire, Yahoo Finance, LinkedIn, SEC documents, or company postings. If your company has an executive appointment announcement related to finance and accounting, please forward to Brandy Fidler at [email protected].